- Home
- UCAR vs APRE Comparison
UCAR vs APRE Comparison
Compare UCAR & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- APRE
- Stock Information
- Founded
- UCAR 2013
- APRE 2006
- Country
- UCAR China
- APRE United States
- Employees
- UCAR N/A
- APRE N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UCAR Consumer Discretionary
- APRE Health Care
- Exchange
- UCAR Nasdaq
- APRE Nasdaq
- Market Cap
- UCAR 8.8M
- APRE 9.4M
- IPO Year
- UCAR 2023
- APRE 2019
- Fundamental
- Price
- UCAR $1.99
- APRE $1.56
- Analyst Decision
- UCAR
- APRE Strong Buy
- Analyst Count
- UCAR 0
- APRE 1
- Target Price
- UCAR N/A
- APRE $20.00
- AVG Volume (30 Days)
- UCAR 56.4K
- APRE 54.2K
- Earning Date
- UCAR 10-07-2025
- APRE 08-12-2025
- Dividend Yield
- UCAR N/A
- APRE N/A
- EPS Growth
- UCAR N/A
- APRE N/A
- EPS
- UCAR N/A
- APRE N/A
- Revenue
- UCAR $6,067,871.00
- APRE $841,012.00
- Revenue This Year
- UCAR N/A
- APRE N/A
- Revenue Next Year
- UCAR N/A
- APRE N/A
- P/E Ratio
- UCAR N/A
- APRE N/A
- Revenue Growth
- UCAR 124.09
- APRE N/A
- 52 Week Low
- UCAR $1.74
- APRE $1.41
- 52 Week High
- UCAR $9.43
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- UCAR 36.07
- APRE 40.41
- Support Level
- UCAR $1.92
- APRE $1.53
- Resistance Level
- UCAR $2.15
- APRE $1.70
- Average True Range (ATR)
- UCAR 0.13
- APRE 0.08
- MACD
- UCAR 0.06
- APRE -0.01
- Stochastic Oscillator
- UCAR 56.16
- APRE 11.06
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.